203 related articles for article (PubMed ID: 29090474)
1. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
[TBL] [Abstract][Full Text] [Related]
2. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
3. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
[TBL] [Abstract][Full Text] [Related]
5. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
6. Mechanically Driven Counter-Regulation of Cortical Bone Formation in Response to Sclerostin-Neutralizing Antibodies.
Gerbaix M; Ammann P; Ferrari S
J Bone Miner Res; 2021 Feb; 36(2):385-399. PubMed ID: 33049076
[TBL] [Abstract][Full Text] [Related]
7. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
[TBL] [Abstract][Full Text] [Related]
9. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists.
Holdsworth G; Greenslade K; Jose J; Stencel Z; Kirby H; Moore A; Ke HZ; Robinson MK
Bone; 2018 Feb; 107():93-103. PubMed ID: 29129759
[TBL] [Abstract][Full Text] [Related]
10. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesis.
McDonald MM; Morse A; Birke O; Yu NYC; Mikulec K; Peacock L; Schindeler A; Liu M; Ke HZ; Little DG
J Orthop Res; 2018 Apr; 36(4):1106-1113. PubMed ID: 28884841
[TBL] [Abstract][Full Text] [Related]
14. Activation of Wnt Signaling by Mechanical Loading Is Impaired in the Bone of Old Mice.
Holguin N; Brodt MD; Silva MJ
J Bone Miner Res; 2016 Dec; 31(12):2215-2226. PubMed ID: 27357062
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.
Tsourdi E; Lademann F; Ominsky MS; Rijntjes E; Köhrle J; Misof BM; Roschger P; Klaushofer K; Hofbauer LC; Rauner M
Endocrinology; 2017 Nov; 158(11):3765-3777. PubMed ID: 28973221
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta.
Sinder BP; Eddy MM; Ominsky MS; Caird MS; Marini JC; Kozloff KM
J Bone Miner Res; 2013 Jan; 28(1):73-80. PubMed ID: 22836659
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent effects of sclerostin antibody on a mouse fracture healing model.
Cui L; Cheng H; Song C; Li C; Simonet WS; Ke HZ; Li G
J Musculoskelet Neuronal Interact; 2013 Jun; 13(2):178-84. PubMed ID: 23728104
[TBL] [Abstract][Full Text] [Related]
18. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
Alzahrani MM; Rauch F; Hamdy RC
Clin Orthop Relat Res; 2016 May; 474(5):1294-302. PubMed ID: 26608966
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability.
Xu C; Ji G; Chen X; Yan L; Liang T; Liu J; Wang F
Connect Tissue Res; 2023 Mar; 64(2):148-160. PubMed ID: 36379907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
